# Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes

> **NCT06069206** · NA · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 500 (actual)

## Conditions studied

- Bloodstream Infection
- Sepsis Bacterial
- MRSA Bacteremia
- Vancomycin

## Interventions

- **OTHER:** T2Bacteria® Panel (direct-from-blood testing)
- **OTHER:** Usual Care

## Key facts

- **NCT ID:** NCT06069206
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-13
- **Primary completion:** 2024-12-14
- **Final completion:** 2025-04-22
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06069206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06069206, "Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06069206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*